Efficacy, Safety and Immunogenicity of GVGH Shigella Sonnei Vaccine (1790GAHB) in a Human Challenge Study of Healthy Non-immune Adults
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2019
Price : $35 *
At a glance
- Drugs Shigella sonnei vaccine (Primary)
- Indications Shigella infections
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 03 Oct 2019 Planned End Date changed from 1 Nov 2019 to 15 Nov 2019.
- 16 May 2019 Planned End Date changed from 21 Oct 2019 to 1 Nov 2019.
- 16 May 2019 Status changed from recruiting to active, no longer recruiting.